July’s Stock Challenge concluded this Friday and throughout the month we had a different leader at the end of each week. After all the shuffling around and 4 lead changes, Pinnacle member “PICONATOR”from the cold land of Whitehorse, Yukon won the challenge in a close finish by edging out FACDIEMEAM (HSYN:OTCPK) by 6%. Both members finished with triple digit returns. PICONATOR won the challenge by selecting PharmaGap Inc. (GAP:TSXV), a relatively unknown company to the community, but one that surely has gained some respect. This was PICONATOR’s first Stock Challenge victory and until this month was relatively unknown within the challenge, never finishing in the top 5. Great win PICONATOR, and welcome to the Stock Star Club!
The Top Ten Leaderboard consisted of many familiar faces, 4 of which were previous Stock Challenge Champions ( TAJITJ, MELODYFAN, MONACO & CHIRO). Previous champion, “CLAYMAN” held the lead going into the final week of the challenge, but was devastated by a poor performance in the final week and settled for a 34th place finish – the largest weekly drop in over six months.
The overall returns this month were well above average; no surprise considering we had one of the best July’s in decades. Only 28 members finished with a negative return on their selection.
August’s Stock Challenge begins on the 4th. Deadline to enter is on Monday August 3rd. To enter, send us the company (with ticker symbol and exchange) you believe will show the highest return for the month of August. Included in your selection entry, you will need to include your PinnacleDigest.com username and hometown. The challenge begins on August 4th and concludes on the 31st. Good Luck! CLICK THIS LINK TO SEND US YOUR SELECTION
About PharmaGap
PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel therapeutic compounds for the treatment of cancer. PharmaGap's research platform targets cellular signalling pathways controlled by Protein Kinase C (PKC) isoforms. PharmaGap's lead drug compound, PhG-alpha-1, is in preclinical development. The Company's strategy is to out-license drug compounds to larger life sciences companies at the preclinical stage.